Global Pulmonary Arterial Hypertension Drugs Market 2023-2027
Technavio has been monitoring the pulmonary arterial hypertension drugs market and is forecast to grow by $2080.07 mn during 2022-2027, accelerating at a CAGR of 6.62% during the forecast period. Our report on the pulmonary arterial hypertension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of PAH, the growing geriatric population, and increased risk factors for cardiovascular diseases.
Technavio's pulmonary arterial hypertension drugs market is segmented as below:
By Route of Administration
By Action Mechanism
- Prostacyclin analogs
- Endothelin receptor antagonists (ERAs)
- Phosphodiesterase (PDE) inhibitors
- Soluble guanylate cyclase stimulators (SGCSs)
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing awareness regarding pah as one of the prime reasons driving the pulmonary arterial hypertension drugs market growth during the next few years. Also, growing technological advancements and new product launches and rising approval of pah drugs will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the pulmonary arterial hypertension drugs market covers the following areas:
- Pulmonary arterial hypertension drugs market sizing
- Pulmonary arterial hypertension drugs market forecast
- Pulmonary arterial hypertension drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary arterial hypertension drugs market vendors that include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc. Also, the pulmonary arterial hypertension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.